Personalis
PSNL | NASDAQ
$14.80
-$0.91 (-5.79%)
At close: Nov 16, 2026, 4:00 PM ET
$14.59
-$0.21 (-1.42%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Personalis Company Profile
Company profile explainedCompany Profile
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Key Executives
| Name | Position |
|---|---|
| Christopher Hall | CEO & Director |
| Aaron L. Tachibana | Chief Financial Officer & Chief Operating Officer |
| Ashish Kheterpal | Senior Vice President & Chief Information Officer |
| Stephen Moore | Senior Vice President, Chief Legal Officer & Corporate Secretary |
| Christian Haudenschild | Senior Vice President of Genomic Science |
| Euan A. Ashley DPHIL FRCP | Co-Founder and Member of Clinical & Scientific Advisory Board |
| Michael Snyder | Co-Founder and Member of Clinical & Scientific Advisory Board |
| Richard Chen | President & Chief Medical Officer |
| Russ Altman | Co-Founder and Member of Clinical & Scientific Advisory Board |
| Stephane Mouradian | Senior Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 425 | Filing |
| Oct 21, 2026 | DEFM14A | Filing |
| Oct 21, 2026 | 425 | Filing |
| Oct 20, 2026 | 425 | Filing |
| Oct 20, 2026 | SC 13E3/A | [Amend] Filing |
| Oct 06, 2026 | 425 | Filing |
| Oct 06, 2026 | 8-K | Current Report |
| Oct 02, 2026 | SC 13E3/A | [Amend] Filing |
| Oct 02, 2026 | CT ORDER | Filing |
| Sep 22, 2026 | 4 | Filing |
Personalis
| Country | United States |
| IPO Date | Jun 20, 2019 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 260 |
| CEO | Christopher Hall |
Contact Details
6600 Dumbarton Circle Fremont,
California 94555 United States
Stock Details
| Ticker Symbol | PSNL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001527753 |
| CUSIP Number | 71535D106 |
| ISIN Number | US71535D1063 |
| SIC Code | 8071 |
Recent News
- 5 days ago / globenewswire.comPSNL Securities Notice: Personalis Shareholders are Notified to Contact BFA Law about its Investigation into the $16.25 per Share Take-Private Merger
- 8 days ago / globenewswire.comPSNL Deal Alert: Personalis $16.25 per Share Merger Under Investigation – Contact BFA Law about the Pending Merger Investigation
- 11 days ago / globenewswire.comPSNL Investigation Reminder: Personalis Shareholders Notified of Investigation into $16.25 per Share Merger – Contact BFA Law
- 13 days ago / globenewswire.comPSNL Investigation Reminder: Personalis $16.25 per Share Merger Triggers Investigation on Behalf of Shareholders – Contact BFA Law if You Hold Shares
- 14 days ago / prnewswire.comPSNL Shareholder Notice: Personalis $16.25 per Share Merger Under Investigation on Behalf of Shareholders
- 15 days ago / businesswire.comPSNL Legal Notice: Personalis Shareholders are Notified to Contact BFA Law About the Ongoing Investigation into the $16.25 per Share Merger
- 18 days ago / globenewswire.comPSNL Investigation Reminder: Personalis' $16.25 per Share Merger Is Under Investigation – Contact BFA Law if You Hold Shares
- 19 days ago / newsfilecorp.comPSNL Merger Notice: BFA Law Notifies Personalis Shareholders of the Ongoing Investigation into the $16.25 per Share Merger
- 20 days ago / globenewswire.com$PSNL Stock Market Alert: Personalis' $16.25 per Share Merger Is Under Investigation – Contact BFA Law if You Are a Shareholder
- 21 days ago / 247wallst.comThe $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings
Add to Watchlist
Select watchlists to add or remove PSNL